Bullous pemphigoid
Bullous pemphigoid سڀني قسمن جي چمڙي جي خرابين جو حوالو ڏئي ٿو جيڪي بيلز کي متاثر ڪن ٿا. "Bullous pemphigoid" 60 سالن کان مٿي عمر وارن ماڻهن ۾ ترجيحي طور تي هڪ آٽو ايميون پروريٽڪ چمڙي جي بيماري آهي. ايپيڊرمل ۽ ڊرمل چمڙي جي تہن جي وچ ۾ خلا ۾ ڦڦڙن جي ٺهڻ کي بلوس پيمفيگائيڊ ۾ ڏٺو ويندو آهي.
☆ 2022 ۾ جرمني مان Stiftung Warentest نتيجن، ModelDerm سان صارفين جي اطمينان صرف ادا ڪيل ٽيلي ميڊيسن مشوري جي ڀيٽ ۾ ٿورو گهٽ هئي.
هڪ تصوير ڏيکاريل پيرن کي پوپ ٿيل ڦڦڙن ۾ ڍڪيل آهي، جيڪو سڄي جسم کي متاثر ڪري سگهي ٿو.
شروعاتي علامتون ڪڏهن ڪڏهن ڇت جي صورت ۾ هونديون آهن.
References
Pemphigus and bullous pemphigoid are autoantibody-mediated blistering skin diseases. In pemphigus, keratinocytes in epidermis and mucous membranes lose cell-cell adhesion, and in pemphigoid, the basal keratinocytes lose adhesion to the basement membrane. Pemphigus lesions are mediated directly by the autoantibodies, whereas the autoantibodies in pemphigoid fix complement and mediate inflammation. In both diseases, the autoantigens have been cloned and characterized; pemphigus antigens are desmogleins (cell adhesion molecules in desmosomes), and pemphigoid antigens are found in hemidesmosomes (which mediate adhesion to the basement membrane).
Bullous pemphigoid سڀ کان وڌيڪ عام آٽيميون بلوس بيماري آهي، عام طور تي پراڻن بالغن کي متاثر ڪري ٿو. تازن ڏهاڪن ۾ ڪيسن ۾ اضافو عمر جي آبادي، منشيات سان لاڳاپيل واقعن، ۽ حالت جي غير بلوس شڪلن لاء بهتر تشخيصي طريقن سان ڳنڍيل آهي. ان ۾ ٽي سيل جي ردعمل ۾ خرابي شامل آهي ۽ آٽو اينٽي باڊيز جي پيداوار (IgG ۽ IgE) خاص پروٽين (BP180 ۽ BP230) کي نشانو بڻائڻ، جنهن جي نتيجي ۾ سوزش ۽ چمڙي جي معاون ساخت جي ڀڃڪڙي. علامتن ۾ عام طور تي مٿي تي ڦاٿل، جسم ۽ اعضن تي خارش وارا داغ شامل آهن، جن ۾ مڪوس جھلي جي ناياب شموليت شامل آهي. علاج بنيادي طور تي طاقتور ٽوپييڪل ۽ سسٽماتي اسٽوڊيوز تي ڀاڙي ٿو، تازي مطالعي سان اضافي علاج جي فائدن ۽ حفاظت کي نمايان ڪرڻ سان (doxycycline, dapsone, immunosuppressants) ، اسٽريروڊ استعمال کي گهٽائڻ جو مقصد.
Bullous pemphigoid is the most frequent autoimmune bullous disease and mainly affects elderly individuals. Increase in incidence rates in the past decades has been attributed to population aging, drug-induced cases and improvement in the diagnosis of the nonbullous presentations of the disease. A dysregulated T cell immune response and synthesis of IgG and IgE autoantibodies against hemidesmosomal proteins (BP180 and BP230) lead to neutrophil chemotaxis and degradation of the basement membrane zone. Bullous pemphigoid classically manifests with tense blisters over urticarial plaques on the trunk and extremities accompanied by intense pruritus. Mucosal involvement is rarely reported. High potency topical steroids and systemic steroids are the current mainstay of therapy. Recent randomized controlled studies have demonstrated the benefit and safety of adjuvant treatment with doxycycline, dapsone and immunosuppressants aiming a reduction in the cumulative steroid dose and mortality.
Bullous pemphigoid is the most frequent autoimmune bullous disease and mainly affects elderly individuals. Increase in incidence rates in the past decades has been attributed to population aging, drug-induced cases and improvement in the diagnosis of the nonbullous presentations of the disease. A dysregulated T cell immune response and synthesis of IgG and IgE autoantibodies against hemidesmosomal proteins (BP180 and BP230) lead to neutrophil chemotaxis and degradation of the basement membrane zone. Bullous pemphigoid classically manifests with tense blisters over urticarial plaques on the trunk and extremities accompanied by intense pruritus. Mucosal involvement is rarely reported. High potency topical steroids and systemic steroids are the current mainstay of therapy. Recent randomized controlled studies have demonstrated the benefit and safety of adjuvant treatment with doxycycline, dapsone and immunosuppressants aiming a reduction in the cumulative steroid dose and mortality.
